Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
Authors' conclusion
Compared with metformin, ipragliflozin improved multiple hepatic steatosis and liver fibrosis indices, suggesting that ipragliflozin exerts potential hepatoprotective effects in early-stage liver disease associated with T2D.
Study context
- Population
- Japanese patients with T2D, body mass index (BMI) ≥22 kg/m² and HbA1c 7%-10%
- Participants
- 103 patients
- Comparison
- Ipragliflozin 50 mg vs metformin 1000 mg for 24 weeks
Methodological detailsprospective, multicentre, open-label, blinded-endpoint
- Prospective
- Multicentre
- Open-label
- Blinded-endpoint
Primary result
As reported in the abstract
Change in Fatty Liver Index (FLI), Ipragliflozin vs Metformin
−9.24 ± 10.7 vs. −3.45 ± 11.8
p = 0.013
Change in Hepatic Steatosis Index (HSI), Ipragliflozin vs Metformin
−1.45 ± 2.32 vs. −0.45 ± 1.87
p = 0.021
Change in Non-alcoholic Fatty Liver Disease-liver Fat Score (NAFLD-LFS), Ipragliflozin vs Metformin
−0.70 ± 1.46 vs. −0.04 ± 0.98
p = 0.011
Change in AST to Platelet Ratio Index (APRI), Ipragliflozin vs Metformin
−0.110 ± 0.323 vs. 0.033 ± 0.181
p = 0.010
Further findings
| Outcome | Ipragliflozin | Metformin |
|---|---|---|
| FLI at baseline | 52.9 ± 26.6 | 57.8 ± 29.0 |
Correlation of changes with visceral fat area (VFA) reduction (Ipragliflozin)
- FLI change vs VFA reduction
- r = 0.340, p = 0.024
- HSI change vs VFA reduction
- r = 0.367, p = 0.011
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →